“I think we are going to see in 2019 that it is a little softer than 2018. We just came off of a 3.5% Real GDP quarter. I think the consensus that a little bit of a slowdown next year is correct. That said what is keeping the economy going is in part a fiscal boost, a little bit on the spending side, and on the tax policy side, both putting cash in people’s pockets.”
Details“We’ve seen three months of strong economic growth in the labor market and we are adding jobs. I’d also just add we are two weeks away of getting the state level numbers and I think that will be informative both with respect to the weather effects and quite frankly some of the political aspects. We will have a better insight as to where these jobs are being created.”
DetailsTomorrow, the American public will get a fresh glimpse at the state of the US labor market. The Bureau of Labor Statistics’ (BLS) release of the September employment report, which will be the next-to-last before the upcoming election, will provide voters new insight on job growth and unemployment rates.
DetailsAs Brill sees it, there are 4 main categories of barriers to biosimilar uptake: reference product manufacturers, biosimilar manufacturers, policy, and education.
DetailsIn a new paper, MGA discusses why the biosimilars market in the United States is not more developed and what steps can be taken to boost competition for biologic drugs. The paper identifies barriers to biosimilars by four categories, related to reference product manufacturers, biosimilar manufacturers, policy, and stakeholder education and awareness. Among the strategies to overcoming barriers are more physician and patient education, competitive biosimilar pricing, action by employer-sponsored health plans and private payors to encourage biosimilar utilization, and continued FDA efforts to support the budding market.
DetailsA new study from MGA examines the practice by brand drug manufacturers of using Risk Evaluation and Mitigation Strategies (REMS) and other forms of restricted access to keep generic manufacturers from obtaining samples needed to develop generic drugs. MGA estimates that this misuse blocks $13.4 billion in generic savings annually, an estimate that has grown nearly 250 percent since MGA’s 2014 analysis of this issue.
DetailsIn the ‘Something More with Chris Boyd’ interview, Brill discusses the state of the economy.
DetailsJust over a year ago, the Food and Drug Administration (FDA) announced a bold new plan to reduce nicotine in cigarettes to non-addictive levels and encourage the development of non-combustible nicotine products. Key to the FDA’s approach is an acknowledgement of both the continuum of risks associated with various nicotine delivery mechanisms and the opportunity for innovative products to reduce the health risks associated with tobacco consumption
Details“…. There are specific issues with regards to our trade relationship with China. But not only with China, with other of our major trading partners around the world. We are better off with good intellectual property laws. We are better off with lower tariff and non-tariff barriers. We need a process that takes us from where we are forward and not backwards, of course.”
DetailsBrill said, “If we take a market-based approach, which we think is a conservative strategy to addressing climate change, we want to use price signals, and a carbon tax is a price signal. It negates the need for…the regulatory toolbox that’s currently being deployed…and allows the market to find…the most efficient way to get emissions down.”
Details
